- GHK-Cu (copper tripeptide-1) is a naturally occurring peptide whose best human evidence is topical and dermatologic, a research area whose participants skew heavily female.
- That makes it a rare case of female-majority representation, but representation is not the same as sex-specific analysis, which remains scarce even here.
- On this site, GHK-Cu also shows why the female-evidence judgment is hand-authored: the automated Female MeSH tag reads zero for it, which is a tagging artifact, not the truth.
Almost every article on this site is about a gap: a compound studied in men and assumed to behave the same in women. GHK-Cu is the interesting exception, and exceptions tend to teach the rule. It is one of the very few compounds in this database whose most relevant human evidence was gathered in a population that skews female, and that alone makes it worth a close look. It also shows the limits of what 'female-majority' actually buys you.
What GHK-Cu is
GHK is a tripeptide, glycyl-L-histidyl-L-lysine, that occurs naturally in human plasma and binds copper to form GHK-Cu (copper tripeptide-1). Its measured levels in the body decline with age. In research it is studied mostly for skin: collagen and extracellular-matrix synthesis, wound healing, and antioxidant activity. It is a mainstay ingredient in cosmetic dermatology, which is exactly why its evidence base looks different from the rest of this database.
Why the evidence skews female
Cosmetic and dermatologic studies, the bulk of GHK-Cu's human research, have historically enrolled predominantly female participants. So unlike a recovery peptide validated in male rats, GHK-Cu's most applicable human data was collected largely in women. That is a genuine, and genuinely rare, advantage. It is worth naming plainly, because honesty about gaps has to include honesty about the exceptions.
The catch: representation isn't analysis
Here is the discipline the rest of the site demands, applied to its own exception. 'Studied mostly in women' is not the same as 'analyzed for female-specific effects.' Even in GHK-Cu's female-heavy literature, results are rarely broken down by hormonal status, cycle phase, or menopause. And the female-majority picture applies to topical use, the systemic and injectable use discussed in some circles is far less studied, in anyone. So the honest summary is narrower than the headline: strong female representation in topical dermatologic research, thin sex-specific analysis, and little systemic data.
A tagging artifact worth seeing
GHK-Cu also makes a useful teaching case about how this database is built. If you look at its profile, or at the female-vs-male evidence chart, the automated Female MeSH tag for GHK-Cu reads zero percent. Taken at face value, that would say no woman was ever studied, which is false. It's an artifact of how sparsely the older dermatologic literature is indexed with sex tags.
If we derived the female-evidence rating from the automated tag, GHK-Cu would look like a compound with no female data, the opposite of the truth. Instead, the qualitative female-evidence judgment on every profile is written by hand, and the automated counts are shown alongside it, labeled as the imperfect proxies they are. GHK-Cu is the clearest case for why those two things must stay separate.
The takeaway isn't that GHK-Cu is proven for women, no compound on this site carries an efficacy claim. It's that when female evidence does exist, we say so as plainly as we say when it doesn't, and we don't let a coarse database tag overwrite what the literature actually shows.